April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
The African Descent and Glaucoma Evaluation Study (ADAGES): Rate and Patterns of Rim Area Loss in Gaucoma Suspects
Author Affiliations & Notes
  • Naira Khachatryan
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Lucie Sharpsten
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Felipe A Medeiros
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Pamela A Sample
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Jeffrey M Liebmann
    New York University School of Medicine, New York, NY
    Department of Ophthalmology, Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, NY
  • Christopher A Girkin
    School of Medicine, University of Alabama at Birmingham, Birmingham, AL
  • Robert N Weinreb
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Naama Hammel
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Linda M Zangwill
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Footnotes
    Commercial Relationships Naira Khachatryan, None; Lucie Sharpsten, None; Felipe Medeiros, Alcon Laboratories Inc (R), Alcon Laboratories Inc (F), Allergan Inc (F), Allergan Inc (R), Allergan, Inc (C), Bausch & Lomb (F), Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec Inc (R), Carl-Zeiss Meditec, Inc (C), Heidelberg Engineering Inc (F), Merck Inc. (F), National Eye Institute (F), Novartis (C), Reichert Inc (R), Reichert, Inc (F), Sensimed (F), Topcon Inc (F); Pamela Sample, None; Jeffrey Liebmann, Alcon, Inc (C), Allergan, Inc (C), Allergan, Inc (F), Bausch & Lomb, Inc (C), Bausch & Lomb, Inc (F), Carl Zeiss Meditech, Inc (F), Diopysis, Inc (C), Diopysis, Inc (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Phamaceuticals, Inc (C), Optovue, Inc (F), Quark Pharmaceuticals, Inc (F), Reichert, Inc (F), Sensimed, Inc (F), Topcon, Inc (F), Valeant Pharmaceutiicals, Inc (C); Christopher Girkin, Carl Zeiss Meditech, Inc (F), Heidelberg Engineering, GmbH (F), SOLX (F); Robert Weinreb, Aerie (F), Alcon (C), Allergan (C), Bausch&Lomb (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Genentech (F), Heidelberg Engineering GmbH (F), National Eye Institute (F), Nidek (F), Novartis (F), Optovue (F), Sensimed (C), Topcon (C), Topcon (F); Naama Hammel, None; Linda Zangwill, Carl Zeiss Meditec Inc (F), Heidelberg Engineering GmbH (F), Nidek Inc (F), Optovue Inc (F), Topcon Medical Systems Inc (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4772. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Naira Khachatryan, Lucie Sharpsten, Felipe A Medeiros, Pamela A Sample, Jeffrey M Liebmann, Christopher A Girkin, Robert N Weinreb, Naama Hammel, Linda M Zangwill; The African Descent and Glaucoma Evaluation Study (ADAGES): Rate and Patterns of Rim Area Loss in Gaucoma Suspects. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4772.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the rate and patterns of rim area loss in glaucoma suspects who developed visual field damage (VFD) to those who did not develop VFD and to assess racial differences in rim loss over time.

Methods: 649 eyes from 366 African (AD) or European descent (ED) glaucoma suspects enrolled in the African Descent and Glaucoma Evaluation Study (ADAGES) were included. All eyes had normal visual field at study entry. Global and sectoral rim area was measured with the Heidelberg Retina Tomograph (HRT) during follow-up. The rates of rim area thinning in AD and ED eyes developing repeatable VFD were compared to those of eyes who did not develop repeatable VFD using multivariate linear mixed-effects models.

Results: 106 eyes (16%) developed VFD during follow up period, including 41/214 (19%) eyes from 122 AD subjects and 65/435 (15%) eyes from 244 ED subjects. Mean follow-up time was 6.6±2.3 years. In univariate and multivariate analyses, the rate of global rim area loss was significantly faster in eyes developing VF damage compared with eyes not developing VF damage and did not differ by race. Specifically, in AD subjects, rates of rim loss were significantly faster in eyes developing VFD compared with eyes not developing VFD in global (multivariate mean -0.0077 mm2/year vs. -0.0040 mm2/year, P=0.024). Similarly, in ED subjects, rates of rim loss were significantly faster in eyes developing VFD compared with eyes not developing VFD in global (multivariate mean -0.0074 mm2/year vs. -0.0033 mm2/year, P=0.031). In both AD and ED subjects, the pattern of rim area loss was similar in the eyes that developed VFD and in eyes that did not; rim area loss tended to be faster in the temporal, temporal inferior and temporal superior regions than in the nasal regions.

Conclusions: In the ADAGES cohort, the rate of rim area loss was faster in eyes that developed VFD compared with eyes that didn't develop VFD. We did not observe racial differences in the rate of rim area loss in glaucoma suspects. Given the pattern of faster rim area loss in temporal sectors was similar in AD and ED eyes that developed VFD and those that did not, it is important to evaluate the magnitude of RA loss to help identify patients at highest risk of VFD. These results suggest that monitoring rate of rim loss may be a useful tool to identify patients at higher risk of VFD.

Keywords: 627 optic disc • 550 imaging/image analysis: clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×